24 Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Certican With Reduced Neoral Versus 3.0g MMF With Standard Dose Neoral In De Novo Heart Transplant Recipients

ID Number 06-0283

Principal Investigator(s)
Sean P Pinney

Department(s) or Division(s)

Research Entity
The Zena and Michael A. Wiener Cardiovascular Institute


This trial will examine the impact of everolimus and reduced cyclosporine on efficacy and renal function compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients. ClinicalTrials.gov Identifier: NCT00300274

Contact Information
Sean Pinney
(212) 241-7300 

Recruiting Patients: No